Abbott Vascular

3200 Lakeside Dr.

Santa Clara

95054

USA

(408) 845-3000

http://www.abbottvascular.com

Product Categories

Embolic Protection Devices, Stents, Stents Drug Eluting, Vascular Closure Devices, Stents Carotid, Stents Peripheral, Stents Bare Metal

Related Content

Abbott announced that the U.S. Food and Drug Administration (FDA) has approved the Aveir single-chamber (VR) leadless pacemaker for the treatment of patients in the U.S. with slow heart rhythms.

News | Pacemakers

Abbott Receives FDA Approval for Aveir VR Leadless Pacemaker System

April 5, 2022 — Abbott announced that the U.S. Food and Drug Administration (FDA) has approved the Aveir single-chamber ...

April 05, 2022

News | Heart Failure

Abbott’s CardioMEMS HF System Receives FDA Approval to Support Patients Battling Earlier-Stage Heart Failure

February 25, 2022 – Abbott has announced that the U.S. Food and Drug Administration (FDA) has approved an expanded ...

February 25, 2022

EnSite X EP mapping system with EnSite Omnipolar Technology provides a 360-degree view of the heart, regardless of catheter orientation. FDA Clears New Cardiac Mapping System to Improve How Doctors Treat Abnormal Heart Rhythms

News | EP Lab

FDA Clears New Cardiac Mapping System to Improve How Doctors Treat Abnormal Heart Rhythms

January 13, 2022 — Abbott received U.S. Food and Drug Administration (FDA) clearance for the EnSite X EP System with ...

January 13, 2022

Abbott plans to expand the monitoring capabilities of its FreeStyle Libre device to enable people to make healthier decisions. The platform uses a disk that is adhered to the skin and uses wireless communication with the patient's smartphone to transfer data into an app where they can monitor their glucose levels in real time without the need for finger prick blood tests. This wearable technology is now being expanded to other areas of biohealth monitoring.

News | Wearables

Abbott Announces Future of Biowearables at Consumer Electronics Show

January 7, 2022 — Abbott announced it is developing a new category of consumer biowearables called Lingo, which is being ...

January 07, 2022

The two FDA-cleared transcatheter LAA occlusion devices on the U.S. market were compared in the SWISS-APERO and SEAL FLX trials presented at TCT 2021. Left is the Abbott Amulet device, right is the newest generation Watchman FLX device.

News | Left Atrial Appendage (LAA) Occluders

First Comparison of Amulet and Watchman FLX LAA Closure Devices Found Similar Outcomes

November 8, 2021 – SWISS-APERO is the first randomized clinical trial comparing the Abbott Amulet left atrial appendage ...

November 08, 2021

Videos | Structural Heart

VIDEO: Abbott Structural Heart CMO Shares Views on Future of Valve Interventions

Dr. Neil Moat, MBBS, chief medical officer of Abbott's structural heart business, was a cardiac surgeon specializing in ...

October 15, 2021

The Abbott Amplatzer Talisman PFO Occlusion System is designed to treat people with a patent foramen ovale (PFO). The small opening between the upper chambers of the heart can increase the risk of recurrent ischemic stroke.

News | Structural Heart Occluders

FDA Clears Abbott Amplatzer Talisman PFO Occluder

October 4, 2021 — U.S. Food and Drug Administration (FDA) has cleared the Abbott Amplatzer Talisman PFO Occlusion System ...

October 04, 2021

CardioMEMS is a wireless, battery-free sensor that is implanted into the pulmonary artery via a right heart catheterization procedure to transmit pulmonary artery pressures.

News | Heart Failure

GUIDE-HF Trial Shows Hemodynamic Guided Management Benefits Larger Heart Failure Population

September 28, 2021 — Hemodynamic guided management using the CardioMEMS device may reduce heart failure hospitalizations ...

September 28, 2021

Illustration of the Watchman transcatheter left atrial appendage (LAA) occluder being deployed into the LAA. FDA is concerned about higher rates of LAA occlusion complications in women compared to men, prompting the FDA to send a letter to providers warning them on possible poor outcomes.

Feature | Left Atrial Appendage (LAA) Occluders

FDA Concerned About Higher Rates of LAA Occlusion Complications in Women

September 27, 2021 — Compared with men undergoing left atrial appendage occlusion (LAAO), women have a significantly ...

September 27, 2021

The U.S. Food and Drug Administration (FDA) has cleared the company's Portico with FlexNav transcatheter aortic valve replacement (TAVR) system to treat people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery.

Feature | Structural Heart Occluders| By Dave Fornell, Editor

FDA Clears Abbott Portico TAVR System to Treat Aortic Valve Disease

September 20, 2021 — Abbott announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Portico ...

September 20, 2021